drugset / Trial / NCT04423055
Nexplanon Use in Women Primarily Choosing a Combined Oral Contraceptive
Phase 4
Completed
120 enrolled
University of California, Davis
Merck Sharp & Dohme LLC · collabUniversity of Colorado, Denver · collabUniversity of Pennsylvania · collab
NaSingle-groupOpen-labelPrevention
Summary
Women currently using or starting a combined oral contraceptive (COC) will be offered study enrollment. Study subjects will have a Nexplanon placed and followed for approximately 12 months to evaluate if they continue the implant, the COC, or both, and to assess bleeding patterns and adverse events.
Timeline
- Start
- 2020-08-13
- Primary completion
- 2024-04-09
- Completion
- 2024-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etonogestrel | Unknown | — | Other |
Indications
No indication recorded.